7 Common Causes Of Snoring

Snoring is a big turn off. It can drive anybody nuts. The last thing you need at the end of a busy day is to hear someone snore. That’s not going to get you any sleep at all.

If you’re the one who snores, chances are, you won’t get any sleep as well. Snorers are likely to wake to their own snores.

Snorers with severe sleep apnea often find themselves waking up gasping for air. People with milder cases of sleep apnea may only wake themselves up just a bit, not enough to remember in the morning but enough to severely disrupt the much-needed sleep cycle.


Since snoring can affect anybody’s sleeping pattern, it makes a lot sense to know the common causes of it. Here are 7 common causes of snoring.

Your mouth anatomy could be the cause of your snoring.

Having a low, thick soft palate can narrow your airway. People who are overweight may have extra tissues in the back of their throats that may narrow their airways. Likewise, if the triangular piece of tissue hanging from the soft palate (uvula) is elongated, airflow can be obstructed and vibration increased.


Think twice about drinking that bottle of beer. Alcohol and other medications can induce snoring.

The root cause of snoring is vibration of the tissues while breathing. Some medications as well as alcohol can lead to enhanced relaxation of muscles

Obese Sleep Apnea Patients May Live Longer With CPAP

Obese people with sleep apnea may live longer when they use a CPAP machine to help keep their airways open while they sleep, a recent study suggests.

After following obese patients with sleep apnea for about 11 years, researchers found those who used the nighttime breathing aid were 42 percent less likely than those who didn’t use the devices to die of any cause.

Apnea that isn’t properly treated has been linked with excessive daytime sleepiness, heart attacks, heart failure and an increased risk of premature death.

“In patients with sleep apnea, there is a poor oxygenation of the body during sleep,” said lead study author Dr. Quentin Lisan of the Paris Cardiovascular Research Center in France.

“This has several consequences, including increased risk of cardiovascular diseases,” Lisan said by email. “PAP therapy allows a better oxygenation of the body during sleep, hence lowering the risk of these associated conditions, which in turn might decrease mortality.”

from Sleep Review http://www.sleepreviewmag.com/2019/04/obese-sleep-apnea/…

Canada Research Award Recipients to Learn More About Whether Cannabis Use Helps with Sleep Apnea, Weakens Immune Response, Alters Breathing Tests

With the recent legalization of recreational cannabis in Canada, a research partnership between The Lung Association – Ontario and Tetra Bio-Pharma has launched to better support patients and healthcare providers with evidence-based information about the impact of cannabis use.At The Lung Association – Ontario’s Breathe! Bash held on March 28, the partnership announced 3 research grant recipients.

The new research investigations are:

  • Jeremy Hirota, PhD, from McMaster University will be determining if smoking cannabis increases the risk of viral respiratory tract infections.
  • Tetyana Kendzerska, MD, PhD, from The Ottawa Hospital Research Institute, University of Ottawa will be filling the knowledge gap on the effects of recreational cannabis on obstructive sleep apnea.
  • Nicholas Vozoris, BSc, MHSc, from St. Michael’s Hospital, University of Toronto, will be examining if smoking cannabis affects breathing tests, and if doctors should be using these tests when seeing patients with lung troubles who smoke cannabis.

“Cannabis is a very polarizing topic, but as scientists we should approach things with data, with experiments to test hypotheses, and then based on the data make an informed decision,” says Jeremy Hirota, assistant professor, McMaster University, in a release.

Kendzerska, associate professor, The Ottawa Hospital Research Institute, University of Ottawa, says, “Despite promising initial findings, there is a need for studies comparing the acute effects of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) on respiratory disturbances during sleep and daytime alertness in people with obstructive sleep apnea in order to provide initial

Treating Excess of One Hormone Shows Promise for Decreasing the Risk of Obstructive Sleep Apnea

A new study finds that treating the overproduction of one hormone may be a way to help a subset of the millions of Americans who suffer from obstructive sleep apnea, reports the University of California-San Francisco.

Researchers at UC San Francisco have found that treating a condition in the adrenal glands causing an excess of aldosterone, a hormone that maintains electrolyte balance and blood pressure, may be an effective way to help people reduce the risk of obstructive sleep apnea.

UCSF endocrine surgeons Insoo Suh, MD, and Quan-Yang Duh, MD, didn’t set out to study sleep apnea. Suh and Duh specialize in the treatment of primary aldosteronism, a disease in which one or both of the adrenal glands overproduce the hormone aldosterone, and were looking into the question of whether this hormone plays a role in obesity. Obesity is a major factor in obstructive sleep apnea, which meant that many of the surgeons’ patients were living with that condition as well.

from Sleep Review http://www.sleepreviewmag.com/2019/04/treating-excess-hormone-sleep-apnea/…

What It’s Really Like to Be a 20-Year-Old College Student With Obstructive Sleep Apnea

Sleep apnea doesn’t only affect middle-aged men, reports Health.com.

Prior to being tested, I had never considered or even discussed the possibility of sleep apnea with my doctor. My doctor doubted that I needed a sleep test because I was so young. It was a surprise to me that this had never been looked into as a diagnosis for me, but I guess it is just that uncommonly diagnosed.

from Sleep Review http://www.sleepreviewmag.com/2019/04/what-its-really-like-to-be-a-20-year-old-college-student-with-obstructive-sleep-apnea/…

NYU School of Medicine Debunks Common Sleep Myths

People often say they can get by on 5 or fewer hours of sleep, that snoring is harmless, and that having a drink helps you to fall asleep.

These are, in fact, among the most widely held myths about sleeping that not only shape poor habits, but may also pose a significant public health threat, according to a new study publishing online in Sleep Health on April 16.

Researchers from NYU School of Medicine reviewed more than 8,000 websites to identify the 20 most common assumptions about sleep. With a team of sleep medicine experts, they ranked them based on whether each could be dispelled as a myth or supported by scientific evidence, and on the harm that the myth could cause.

“Sleep is a vital part of life that affects our productivity, mood, and general health and well-being,” says study lead investigator, Rebecca Robbins, PhD, a postdoctoral research fellow in the Department of Population Health at NYU Langone Health, in a release. “Dispelling myths about sleep promotes healthier sleep habits which, in turn, promote overall better health.”

The claim by some people that they can get by on 5 hours of sleep was among the top myths researchers were able to dispel based on scientific evidence. They say this myth also poses the most serious risk to health from long-term sleep deficits. To avoid the effects of this falsehood and others identified in this study, such as the value

Upper Airway Stimulation’s Impact on Sleep Apnea Comorbidities

The Inspire implant has been shown to improve sleepiness and functional outcomes. Now researchers are looking at whether it also helps with comorbid disorders, such as insomnia and depression.

When you have a tricky obstructive sleep apnea (OSA) patient who just can’t seem to tolerate CPAP, when adjusting the airflow pressure doesn’t seem to help, and when oral appliances aren’t successful at decreasing the patient’s apneas throughout the night; you might think about adding another method to your toolbox. Upper airway stimulation is still relatively new, but more research is coming out to show how this therapy could be an alternative treatment when CPAP fails.

According to an abstract that will be presented at the American Academy of Neurology (AAN) meeting in May, upper airway stimulation could also be effective at decreasing some comorbidities, including insomnia and depression.

“We showed clinically meaningful, significant improvement in people’s lives, that, you know, don’t always get looked at,” says Tina Waters, MD, a coauthor of the research and a neurologist sleep specialist at the Cleveland Clinic in Cleveland, Ohio.

According to Waters, demonstrating that upper airway stimulation for OSA reduces insomnia and depression is not necessarily surprising. But studies like this one are still important to substantiate that upper airway stimulation measures up to other OSA treatments.

The upper airway stimulation therapy analyzed in this study is sold under the brand name Inspire . It was approved by the

ResMed AirFit P30i, Top-of-head-connected Nasal Pillows Mask

ResMed has unveiled its second top-of-head-connected CPAP mask for treating sleep apnea, a new nasal pillows option, AirFit P30i.

The mask’s “tube-up” connection, also featured on ResMed’s AirFit N30i nasal mask released in January, keeps tubing out of the wearer’s way so they can move and sleep in any position.

According to ResMed, AirFit P30i fits 90% of wearers with its two frame sizes and three cushions, helping home medical equipment (HME) providers fit patients easier and faster.

“The AirFit P30i provides great freedom of movement for patients who want an unobtrusive nasal pillows mask,” says Jim Hollingshead, president of ResMed’s Sleep business, in a release. “This unique pillows tube-up frame is a great addition to our growing mask family, and it’s easy for sleep labs and HMEs to stock and fit.”


A ResMed-guided external clinical study of 22 current nasal pillows users from May to June 2018 in Sydney, Australia, comparing AirFit P30i to another tube-up nasal pillows mask found:

  • CPAP users preferred AirFit P30i nearly 2 to 1.
  • More than 70% whose preference was based on mask seal preferred AirFit P30i.
  • Twice as many reported AirFit P30i is easier to use and more comfortable.

As of April 15, AirFit P30i is available throughout the United States, Canada, Europe, Australia, and New Zealand. It will be available in other countries later this year.

The mask joins ResMed’s portfolio of 30-plus CPAP masks, including its “tube-down” nasal pillows mask, AirFit

How Your Mattress Impacts On Allergies

Allergies affect over 21 million adults in the UK and 59% of indoor allergy sufferers say their symptoms feel worse in the bedroom. The dreaded house dust mite is one of the most common triggers for an allergic reaction. And the hub of these dust mites is your bed – one of their favourite places to live.

The post How Your Mattress Impacts On Allergies appeared first on The Sleep Council.

from The Sleep Council https://sleepcouncil.org.uk/mattress-impacts-allergies/…

Analyzing ASV in People with Heart Failure and Sleep-disordered Breathing

New insights from the CAT-HF trial show promise for subsets of patients who use adaptive servo-ventilation, but larger studies are needed.

In 2015, when the results of Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure (SERVE-HF) trial were released, it sent ripples through the sleep medicine world.

The clinical trial that involved 1,325 patients with heart failure with reduced ejection fraction (HFrEF) and central sleep apnea showed that the patients who were treated with adaptive servo-ventilation (ASV) had a higher risk of all-cause mortality and cardiovascular mortality than those who were treated with conventional heart failure management.1 These findings led to safety notices issued by the likes of the American Academy of Sleep Medicine (AASM) and have made sleep providers cautious of prescribing ASV therapy to patients with heart failure.

But recent insights from the Cardiovascular Improvements with Minute Ventilation-targeted Adaptive Servo-Ventilation Therapy in Heart-Failure (CAT-HF) trial suggest that ASV therapy could improve cardiovascular outcomes for a subset of patients with moderate-to-severe sleep disordered breathing (either because of obstructive or central sleep apnea). Like SERVE-HF, CAT-HF was funded by ResMed, which markets an ASV device.

The CAT-HF trial looked at the effect ASV therapy has on patients hospitalized for acute decompensated heart failure and who have moderate-to-severe sleep apnea. While the study found that adding ASV to optimized medical therapy didn’t improve 6-month cardiovascular outcomes, it did find that patients